On the other hand, Zhang et al. [74] investigated biomarkers of neoadjuvant activity of a TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2+ BC patients with metabolomics and transcriptomics. This evidence concerns the gene ERBB2 and breast cancer.